UTR Therapeutics Inc. Announces U.S. FDA Orphan Drug Designation and Rare Pediatric Disease Designation for UTRxMYCN M1-14

RegulatoryUTRxMYCN M1-14Positive

AI Analysis

Summary

UTR Therapeutics announced FDA Orphan Drug Designation and Rare Pediatric Disease Designation for UTRxMYCN M1-14, a therapeutic targeting MYCN in rare, aggressive soft tissue sarcomas. The designations address an unmet clinical need in pediatric and adult sarcoma treatment.

Outcome Details

Orphan Drug Designation and Rare Pediatric Disease Designation granted

Importance:6/10

Sentiment:

0.70

orphan drug designationrare pediatric disease designationsoft tissue sarcomaMYCN targetingpediatric oncology

Read the original article

Published by PR Newswire Biotech on September 29, 2026 4:21 PM

Read Original